Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "C"

9939 News Found

Zydus Lifesciences reports strong Q3 & 9M FY26 growth
News | February 10, 2026

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million


Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26
News | February 10, 2026

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year


Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
News | February 09, 2026

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses


HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
News | February 09, 2026

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

HCG clinicians contributing to one of the largest bodies of oncology research from India


Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
News | February 09, 2026

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26


DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
News | February 09, 2026

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments


Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
News | February 09, 2026

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution


Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
News | February 09, 2026

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer